Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Diab Vasc Dis Res ; 9(1): 42-51, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22045866

RESUMO

Hyperglycaemia and glucose degradation products (GDPs) are closely associated with oxidative stress and inflammation in diabetic patients, a condition that leads to endothelial dysfunction and cardiovascular problems. We evaluated the effect of citrate and gluconate on glucose- and GDP-induced endothelial inflammation by measuring changes in viability, inflammation and function in primary human umbilical vein endothelial cells (HUVECs). The extent of apoptosis/necrosis was measured by flow cytometry and visualised with confocal microscopy by staining with annexin V or propidium iodide, respectively. Protein kinase C-ßII (PKC-ßII) activation was evaluated with Western blotting. Incubation with glucose (30 mM) and GDP (50 µM) significantly increased PKC-ßII expression, endothelial cell death and inflammation. The addition of citrate decreased hyperglycaemia-induced apoptosis (p = 0.021), necrosis (p = 0.04) and reduced PKC-ßII expression (p = 0.021) down to background levels. Citrate improved endothelial function by reducing the inflammatory markers (p = 0.01) and by decreasing neutrophil diapedesis (p = 0.012). These results suggest that citrate may have therapeutic potential by reducing hyperglycaemia-induced endothelial inflammation and abolishing endothelial dysfunction.


Assuntos
Anti-Inflamatórios/farmacologia , Apoptose/efeitos dos fármacos , Ácido Cítrico/farmacologia , Glucose/metabolismo , Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos , Hiperglicemia/metabolismo , Inflamação/metabolismo , Western Blotting , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Técnicas de Cocultura , Ativação Enzimática , Citometria de Fluxo , Gluconatos/farmacologia , Células Endoteliais da Veia Umbilical Humana/metabolismo , Células Endoteliais da Veia Umbilical Humana/patologia , Humanos , Hiperglicemia/patologia , Inflamação/patologia , Molécula 1 de Adesão Intercelular/metabolismo , Microscopia Confocal , Necrose , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Proteína Quinase C/metabolismo , Proteína Quinase C beta , Pironas/metabolismo , Migração Transendotelial e Transepitelial/efeitos dos fármacos
2.
Intensive Care Med ; 36(7): 1213-20, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20397009

RESUMO

PURPOSE: Glucose degradation products (GDPs) are precursors of advanced glycation end products (AGEs) that cause cellular damage and inflammation. We examined the content of GDPs in commercially available glucose-containing infusion fluids and investigated whether GDPs are found in patients' blood. METHODS: The content of GDPs was examined in infusion fluids by high-performance liquid chromatography (HPLC) analysis. To investigate whether GDPs also are found in patients, we included 11 patients who received glucose fluids (standard group) during and after their surgery and 11 control patients receiving buffered saline (control group). Blood samples were analyzed for GDP content and carboxymethyllysine (CML), as a measure of AGE formation. The influence of heat-sterilized fluids on cell viability and cell function upon infection was investigated. RESULTS: All investigated fluids contained high concentrations of GDPs, such as 3-deoxyglucosone (3-DG). Serum concentration of 3-DG increased rapidly by a factor of eight in patients receiving standard therapy. Serum CML levels increased significantly and showed linear correlation with the amount of infused 3-DG. There was no increase in serum 3-DG or CML concentrations in the control group. The concentration of GDPs in most of the tested fluids damaged neutrophils, reducing their cytokine secretion, and inhibited microbial killing. CONCLUSIONS: These findings indicate that normal standard fluid therapy involves unwanted infusion of GDPs. Reduction of the content of GDPs in commonly used infusion fluids may improve cell function, and possibly also organ function, in intensive-care patients.


Assuntos
Hidratação/métodos , Glucose/análise , Produtos Finais de Glicação Avançada/sangue , Soluções Farmacêuticas/química , Cuidados Críticos/métodos , Contaminação de Medicamentos , Feminino , Glucose/administração & dosagem , Humanos , Soluções Isotônicas/química , Masculino , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Solução Salina Hipertônica/química , Esterilização
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA